Browsing by Author "Triggianese P."

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    A patient-driven registry on Behçet’s disease: the AIDA for patients pilot project
    (Frontiers Media SA, 2023) Gaggiano C.; Del Bianco A.; Sota J.; Gentileschi S.; Ruscitti P.; Giacomelli R.; Piga M.; Crisafulli F.; Monti S.; Emmi G.; De Paulis A.; Vitale A.; Tarsia M.; Caggiano V.; Nuzzolese R.; Parretti V.; Fabiani C.; Lopalco G.; Maier A.; Cattalini M.; Rigante D.; Govoni M.; Li Gobbi F.; Guiducci S.; Parronchi P.; Marino A.; Ciccia F.; Maggio M.C.; Aragona E.; Bartoloni E.; Iagnocco A.; Viapiana O.; Sebastiani G.D.; Guerriero S.; Insalaco A.; Del Giudice E.; Conti G.; Barone P.; Olivieri A.N.; Brucato A.; Carubbi F.; Triggianese P.; Mauro A.; Tosi G.M.; Fonollosa A.; Giardini H.A.M.; Ragab G.; Tharwat S.; Hernández-Rodríguez J.; Sfikakis P.P.; Laskari K.; Karamanakos A.; Espinosa G.; Shahram F.; Direskeneli H.; Hinojosa-Azaola A.; Opris-Belinski D.; AlMaghlouth I.A.; Hatemi G.; Eksin M.A.; Önen F.; Więsik-Szewczyk E.; Akkoç N.; Tufan A.; Şahin A.; Erten Ş.; Ozen S.; Batu E.D.; Frediani B.; Balistreri A.; Cantarini L.
    Introduction: This paper describes the creation and preliminary results of a patient-driven registry for the collection of patient-reported outcomes (PROs) and patient-reported experiences (PREs) in Behçet’s disease (BD). Methods: The project was coordinated by the University of Siena and the Italian patient advocacy organization SIMBA (Associazione Italiana Sindrome e Malattia di Behçet), in the context of the AIDA (AutoInflammatory Diseases Alliance) Network programme. Quality of life, fatigue, socioeconomic impact of the disease and therapeutic adherence were selected as core domains to include in the registry. Results: Respondents were reached via SIMBA communication channels in 167 cases (83.5%) and the AIDA Network affiliated clinical centers in 33 cases (16.5%). The median value of the Behçet’s Disease Quality of Life (BDQoL) score was 14 (IQR 11, range 0–30), indicating a medium quality of life, and the median Global Fatigue Index (GFI) was 38.7 (IQR 10.9, range 1–50), expressing a significant level of fatigue. The mean Beliefs about Medicines Questionnaire (BMQ) necessity-concern differential was 0.9 ± 1.1 (range – 1.8–4), showing that the registry participants prioritized necessity belief over concerns to a limited extent. As for the socioeconomic impact of BD, in 104 out of 187 cases (55.6%), patients had to pay from their own pocket for medical exams required to reach the diagnosis. The low family socioeconomic status (p < 0.001), the presence of any major organ involvement (p < 0.031), the presence of gastro-intestinal (p < 0.001), neurological (p = 0.012) and musculoskeletal (p = 0.022) symptoms, recurrent fever (p = 0.002), and headache (p < 0.001) were associated to a higher number of accesses to the healthcare system. Multiple linear regression showed that the BDQoL score could significantly predict the global socioeconomic impact of BD (F = 14.519, OR 1.162 [CI 0.557–1.766], p < 0.001). Discussion: Preliminary results from the AIDA for Patients BD registry were consistent with data available in the literature, confirming that PROs and PREs could be easily provided by the patient remotely to integrate physician-driven registries with complementary and reliable information. Copyright © 2023 Gaggiano, Del Bianco, Sota, Gentileschi, Ruscitti, Giacomelli, Piga, Crisafulli, Monti, Emmi, De Paulis, Vitale, Tarsia, Caggiano, Nuzzolese, Parretti, Fabiani, Lopalco, Maier, Cattalini, Rigante, Govoni, Li Gobbi, Guiducci, Parronchi, Marino, Ciccia, Maggio, Aragona, Bartoloni, Iagnocco, Viapiana, Sebastiani, Guerriero, Insalaco, Del Giudice, Conti, Barone, Olivieri, Brucato, Carubbi, Triggianese, Mauro, Tosi, Fonollosa, Giardini, Ragab, Tharwat, Hernández-Rodríguez, Sfikakis, Laskari, Karamanakos, Espinosa, Shahram, Direskeneli, Hinojosa-Azaola, Opris-Belinski, AlMaghlouth, Hatemi, Eksin, Önen, Więsik-Szewczyk, Akkoç, Tufan, Şahin, Erten, Ozen, Batu, Frediani, Balistreri and Cantarini.
  • No Thumbnail Available
    Item
    Influence of gender on Behçet's disease phenotype and irreversible organ damage: Data from the International AIDA Network Behçet's Disease Registry
    (Elsevier Masson s.r.l., 2025) Sota J.; Ragab G.; AlMaglouth I.; Lopalco G.; Tufan A.; Direskeneli H.; Hinojosa-Azaola A.; Mayrink Giardini H.A.; Guerriero S.; Triggianese P.; Sfikakis P.P.; Piga M.; Ruscitti P.; Govoni M.; Iagnocco A.; Carubbi F.; Hernández-Rodríguez J.; Laymouna A.H.; Mahmoud A.A.-M.A.; Ghanema M.; Aboabat A.A.; Asfina K.N.; Alanazi F.; Morrone M.; Spedicato V.; Kucuk H.; Kardas R.; Alibaz Öner F.; Sevik G.; Torres-Ruiz J.; Kawakami-Campos P.A.; Parente de Brito Antonelli I.; Dammacco R.; Chimenti M.S.; Arida K.; Floris A.; Gentile M.; Ruffilli F.; Bellis E.; Alunno A.; Espinosa G.; Gentileschi S.; Gaggiano C.; Vitale A.; Caggiano V.; Lopez R.; Tarsia M.; Monti S.; Hatemi G.; Karakoç A.; Frassi M.; Giacomelli R.; Tharwat S.; Thabet M.; Ciccia F.; Emmi G.; Viapiana O.; Şahin A.; Sebastiani G.D.; Batu E.D.; Ozen S.; Sener S.; Opris-Belinski D.; Costi S.; Conforti A.; Cattalini M.; Bartoloni E.; Akkoç N.; Gunduz O.S.; Conti G.; Maier A.; Giardina A.; Li Gobbi F.; Parronchi P.; Sarzi Puttini P.; Breda L.; De Paulis A.; Carreño E.; La Torre F.; Więsik-Scewczyk E.; de-la Torre A.; Mejía-Salgado G.; Shahram F.; Guiducci S.; Maggio M.C.; Aragona E.; Rigante D.; Ciavarro A.; Önen F.; Erten; Insalaco A.; Del Giudice E.; Barone P.; Gicchino F.; Brucato A.; Lo Gullo A.; Mauro A.; Karamanakos A.; Balistreri A.; Mazzei M.A.; Frediani B.; Fabiani C.; Cantarini L.
    Objectives: Gender impact on phenotypical expression of Behçet's disease (BD) has been specifically investigated only in a few large-scale studies. The main goal of the study was to examine gender differences in a large cohort of patients affected by BD. Methods: Data were retrieved from the International AIDA Network Registry for BD. We assessed differences between males and females in terms of Behçet's syndrome Overall Damage Index (BODI), differences in the disease manifestations at onset and in the cumulative manifestations throughout disease course, as well as differences in the cardiovascular risk. Finally, predictive factors leading to major organ involvement were investigated. Results: In total, 1024 BD patients (567 males, 457 females) were enrolled in the study, with a male-to-female ratio of 1.24/1. Males displayed a significantly higher mean ± SD BODI (1.92 ± 2.09) at the last follow-up, compared to female patients (1.25 ± 1.87) (P < 0.0001). Uveitis (P < 0.0001) and vascular involvement (P = 0.0076) were significantly more frequent among males whereas female patients were significantly over-represented in arthralgia (P < 0.0001), arthritis (P = 0.00025), isolated headache (P < 0.0001), central nervous system (CNS) involvement (P = 0.040), and gastrointestinal involvement (P = 0.00046). Regarding cardiovascular risk, no differences between the two groups emerged (P = 0.617). Four variables were associated with the development of major organ involvement: male gender (OR = 2.104, P = 0.001), current treatment with biologic agents (OR = 2.257, P = 0.0003), origin from endemic countries (OR = 2.661, P = 0.0009), and disease duration (OR = 1.002, P = 0.024). Conclusion: BD displays a more severe course among males. This subgroup develops more irreversible damage and presents more frequently ocular and vascular involvement during disease course. On the other hand, female patients are prone to experience articular involvement, headache, CNS and gastrointestinal involvement. These data suggest the existence of a gender-driven disease expression. © 2024 The Author(s)
  • No Thumbnail Available
    Item
    Impact of HLA-B51 on Uveitis and Retinal Vasculitis: Data from the AIDA International Network Registries on Ocular Inflammatory Disorders
    (Taylor and Francis Ltd., 2025) Sota J.; Guerriero S.; Lopalco G.; Tufan A.; Ragab G.; AlMaglouth I.; Govoni M.; Sfikakis P.P.; Frassi M.; Vitale A.; Kardas R.C.; Triggianese P.; Chimenti M.S.; Aboabat A.A.; Piga M.; Monti S.; Sebastiani G.D.; Yildirim D.; Conforti A.; Gentileschi S.; Dammacco R.; Hinojosa-Azaola A.; Kawakami-Campos P.A.; Ruffilli F.; Torres-Ruiz J.; Thabet M.; Atig A.; Ruscitti P.; Cataldi G.; Viapiana O.; Hatemi G.; Karakoç A.; Costi S.; Iagnocco A.; Crisafulli F.; Fragoulis G.; Del Giudice E.; Hegazy M.T.; Paroli M.P.; Şahin A.; Morrone M.; Iannone F.; Opris-Belinski D.; Asfina K.N.; Barone P.; Gaggiano C.; Kucuk H.; Gicchino M.F.; Carubbi F.; Caggiano V.; Laskari K.; Tharwat S.; Direskeneli H.; Alibaz-Oner F.; Sevik G.; Maier A.; Laymouna A.H.; Emmi G.; Akkoç N.; Tarsia M.; Sbalchiero J.; Conti G.; Spinella R.; La Torre F.; Tombetti E.; Amin R.H.; Mauro A.; Karamanakos A.; Carreño E.; Fonollosa A.; Cattalini M.; Breda L.; de-la-Torre A.; Wiesik-Szewczyk E.; Cifuentes-González C.; Ozen S.; Mazzei M.A.; Tosi G.M.; Frediani B.; Balistreri A.; Batu E.D.; Gupta V.; Cantarini L.; Fabiani C.
    Purpose: The clinical relevance of human leukocyte antigen (HLA) subtypes such as HLA-B51 on Behçet’s disease (BD)-related uveitis and non-infectious uveitis (NIU) unrelated to BD remains largely unknown. Methods: Data were prospectively collected from the International AIDA Network Registry for BD and for NIU. We assessed differences between groups (NIU unrelated to BD and positive for HLA-B51, BD-related uveitis positive for HLA-B51 and BD-related uveitis negative for HLA-B51) in terms of long-term ocular complications, visual acuity (VA) measured by best corrected visual acuity (BCVA), anatomical pattern, occurrence of retinal vasculitis (RV) and macular edema over time. Results: Records of 213 patients (341 eyes) were analyzed. No differences in complications were observed (p = 0.465). With regard to VA, a significant difference was detected in median BCVA (p = 0.046), which was not maintained after Bonferroni correction (p = 0.060). RV was significantly more prevalent in NIU-affected patients who tested positive for HLA-B51, irrespective of the systemic diagnosis of BD (p = 0.025). No differences emerged in the occurrence of macular edema (p = 0.99). Conclusions: Patients with NIU testing positive for HLA-B51 exhibit an increased likelihood of RV throughout disease course, irrespective of a systemic diagnosis of BD. The rate of complications as well as VA are comparable between NIU cases unrelated to BD testing positive for HLA-B51 and uveitis associated with BD. Therefore, it is advisable to perform the HLA-B typing in patients with NIU or retinal vasculitis, even in the absence of typical BD features. © 2024 Taylor & Francis Group, LLC.